-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 1, Zhejiang Xianju Pharmaceutical issued an announcement stating that the company had recently received the "Drug Supplementary Application Approval Notice" (notice number: 2021B01595) on ropivacaine hydrochloride injection approved and issued by the National Medical Products Administration.
The basic information of the drug is as follows:
It is reported that ropivacaine hydrochloride injection is the first pure L-body long-acting amide local anesthetic.
Ropivacaine Hydrochloride Injection was developed in 1994 by Astra Company of Sweden (the company merged with the British Zeleca Company to form AstraZeneca Pharmaceutical Co.